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Abstract We are now showing that cultured human melanoma
cells can synthesize steroids such as corticosterone from
progesterone or deoxycorticosterone. Corticosterone production
is strongly responsive to deoxycorticosterone substrate addition
(12-fold increase), but unresponsive to the adrenal stimulating
factors ACTH and angiotensin II. This is the first demonstration
that skin cells (malignant melanocytes) have the capability to
synthesize 11-deoxycorticosterone, corticosterone, and 18-hy-
droxydeoxycorticosterone.
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1. Introduction
The adrenal gland is the main site of mineralo- and gluco-
corticosteroid production [1]. The gonads represent additional
classical endocrine organs that can produce corticosteroids,
but in smaller quantities [1]. However, recent evidence has
shown that corticosteroids can also be produced at extraendo-
crine sites [2^4]. Production of corticosterone and aldosterone
has been already documented in the brain [2] and vascular
system [3], while production of 11-deoxycortisol and 11-
deoxycorticosterone was demonstrated in lymphocytes [4].
In the adrenal gland, the most important regulator of glu-
cocorticoid biosynthesis and release to the systemic circulation
is pituitary adrenocorticotropin (ACTH) that derives from the
precursor proopiomelanocortin (POMC) protein, after stimu-
lation by corticotropin releasing hormone (CRH) [1]. Miner-
alocorticoid production is, in contrast, controlled by the re-
nin-angiotensin system through its e¡ector angiotensin II (A-
II) [1]. Skin, the largest body organ, also has the capability to
produce CRH and POMC derived peptides, perhaps as part
of a local defense against stressful stimuli [5^7]. Moreover, we
reported that human skin cells express the ACTH receptor
gene (MC2), and produce mRNAs for three obligatory en-
zymes of steroid synthesis, the cytochromes P450scc
(CYP11A1), P450c17 (CYP17) and P450c21 (CYP21A2)[8].
This raised the question on whether selected corticosteroids
could be produced locally in the skin (cf. 6, 8). Therefore, we
investigated if a human melanoma line, shown to express
CRH, POMC, CYP17 and CYP21A2 genes, could metabolize
progesterone and deoxycorticosterone substrates to biologi-
cally active corticosteroids.
2. Materials and methods
2.1. Materials
14C-progesterone (14C-PROG), 3H-progesterone (3H-PROG) and
3H-deoxycorticosterone (3H-DOC) were from NEN life Sciences (Bos-
ton, MA, USA). ACTH-1^24 was purchased from Organon (West
Orange, NJ, USA). (Sar1)angiotensin II (A-II), progesterone
(PROG), deoxycorticosterone (DOC), corticosterone, 18-hydroxy-
deoxycorticosterone (18OHDOC) and aldosterone (Aldo) were from
Sigma Chemical Company (St. Louis, MO, USA). Ham F-10, fetal
bovine serum, Hank’s balanced salt solution (HBSS), antibiotic anti-
mycotic mixture were purchased from GIBCO (Grand Island, NY,
USA).
2.2. Cell culture
Semi-con£uent cultures of the human melanoma SK-MEL188 cells
were maintained serum at 37‡C in the presence of 5% CO2 in Ham F-
10 medium with added antibiotics and 10% fetal bovine, as described
previously [9,10]. Media were changed every 48 h.
For experimental treatment, melanoma cells were plated in 6-well
dishes, grown near con£uence and the medium was replaced by Ham’s
F-10 without serum. The cells were then incubated for 24 h in serum
free medium containing 1 WM DOC, in the presence or absence of A-
II (1037 M) or ACTH-1^24 (1038 M). The media were collected and
assayed for aldosterone and corticosterone using an ELISA as de-
scribed previously [3,11].
2.3. Identi¢cation of radioactive metabolites
Labeling with radioactive steroid substrates and identi¢cation of
metabolites followed the methodology described previously [3,11].
Brie£y, mixtures of 14C-PROG (1 WCi), 3H-PROG (25 WCi) or 3H-
DOC (25 WCi), with unlabeled PROG or DOC, respectively, to the
¢nal concentration of 1 WM, were added to the culture medium. After
24 h, media were collected, extracted using a C18 Bond Elut solid
phase extraction column (Varian Corporation, Palo Alto, CA, USA).
Steroids were eluted with ethyl acetate and evaporated in siliconized
tubes to which the unlabeled standards dissolved in ethanol were
added; in the experiments of incubation with 3H-PROG, unlabeled
steroids were not added and the extract was used directly for RP-
HPLC. The steroid mixtures were spotted onto a Whatman LK5F
TLC plate and developed in chloroform/methanol/water at ratios
100/5/0.1 for DOC and 100/3/0.1 for PROG. The radioactive products
from the progesterone incubation were visualized by autoradiography
using Kodak LE intensifying screen after 3 weeks exposure at 370‡C.
The unlabeled standards were visualized under UV light.
For reversed phase high-performance liquid chromatography (RP-
HPLC) the radioactive products from the tritiated precursors that
migrated in the TLC at the positions corresponding to Aldo, DOC,
corticosterone and 18OHDOC standards were eluted with isopropa-
nol [3,11]. The eluted fractions were evaporated and suspended in
methanol water and subjected to RP-HPLC separation on Hypersil
column (250U4.6 mm; 5 Wm particle size; Alltech, Deer¢eld, IL,
USA). Separation was performed using a 49^56% methanol elution
gradient over 75 min and fractions were collected every minute and
counted. The measured radioactivity was then matched to the UV
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peaks of unlabeled standards. In the case of incubation with 3H-
PROG (1 WM), the fractions were also assayed for corticosterone
using an ELISA as detailed previously [3,11].
3. Results and discussion
Our previous molecular analyses documented that the SK-
Mel188 melanoma cells express CYP17 and CYP21A2 genes
[8]. Speci¢cally, the predicted 158 bp product from exon 1 of
CYP17, and the 306 bp product corresponding to the spliced
mRNA fragment from the exons 9 and 10 of CYP21A2 were
detected by RT-PCR followed by Southern blot hybridization
to the oligonucleotide probe containing the sequence in the
ampli¢ed fragment [8]. To test whether this expression is ac-
companied by the actual synthesis of corticosteroids, we ini-
tially incubated melanoma cells with 14C-PROG. The auto-
radiogram from the cell culture incubated with 14C-PROG
showed rapid substrate metabolism, that resulted in complete
disappearance from the culture media by 24 h (Fig. 1). The
autoradiography of the TLC separated products also showed
several radioactive products; the predominant steroids mi-
grated at the same rate as the deoxycorticosterone (DOC)
and corticosterone (B) standards (Fig. 1). Aldosterone pro-
duction was below the level of detectability under tested con-
ditions.
To characterize further this process we used 3H-DOC as the
substrate (Figs. 2 and 3). The fractions eluted from the TLC
plates were separated by RP-HPLC. Radioactive peaks with
Fig. 1. TLC separation of the products of 14C-progesterone metabo-
lism by melanoma cells after 24 h of incubation. PROG, progester-
one; DOC, 11-deoxycorticosterone; B, corticosterone; Aldo, aldos-
terone; 11-dehydro-B, 11-deoxydrocorticosterone.
Fig. 2. RP-HPLC identi¢cation of 3H-corticosterone as metabolite
of 3H-DOC. Upper panel: UV detection of 11-dehydrocorticoster-
one (A) and corticosterone (B) standards. Lower panel: Radioactiv-
ity in eluted fractions with arrow indicating 3H-corticosterone peak.
Fig. 3. RP-HPLC identi¢cation of 3H-18OHDOC as metabolite of
3H-DOC. Upper panel: UV detection of 18OHDOC standard. Low-
er panel: Radioactivity in eluted fractions with arrow indicating 3H-
18OHDOC peak.
Fig. 4. ELISA identi¢cation of corticosterone (B) in RP-HPLC sep-
arated fractions. Upper panel: UV detection of corticosterone (B)
standard. Lower panel: Amount of immunoreactive corticosterone
(arrow) in media from human melanoma cells incubated with pro-
gesterone. Control represents media from cells cultured without pro-
gesterone added.
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retention times corresponding to those of corticosterone (B)
and 18OHDOC were then identi¢ed (Figs. 2 and 3); in con-
trast, at the elution time of aldosterone, only background
radioactivity was seen. Thus, both TLC and RP-HPLC anal-
yses showed that melanoma cells can selectively transform
14C-PROG or 3H-DOC to corticosterone (B) and 18OHDOC
radioderivatives.
Finally, we used 3H-PROG as the substrate (Fig. 4). The
fractions eluted from TLC plates were again separated by RP-
HPLC, divided and submitted separately for liquid scintilla-
tion spectroscopy and ELISA assay for corticosterone. The
liquid scintillation spectroscopy showed again the radioactive
peak corresponding to elution time of DOC and a small ra-
dioactive peak corresponding to the elution time of cortico-
sterone (not shown). The collected fractions were analyzed
thereafter by ELISA that showed corticosterone (B) immu-
noreactivity at the same elution time as the corticosterone
standard (Fig. 4). Thus, this assay con¢rmed that melanoma
cells transform PROG to corticosterone (B).
The accumulation rate of corticosterone and aldosterone
was then measured by ELISA using speci¢c antibodies against
those steroids (Table 1). Because each con£uent well from a
6-well plate contains approximately 106 human melanoma
cells, the reported net production/well would correspond to
the activity of approximately 106 of human melanoma cells.
The concentration of corticosterone in conditioned serum free
media from the melanoma cells cultured in the presence of 1
WM DOC was 540 pg/well, compared to only 44.4 pg/well in
control media (no addition of DOC) (Table 1). Thus, supply-
ing cells with metabolic precursor (DOC) signi¢cantly stimu-
lated corticosterone production (12 times) and had no e¡ect on
aldosterone production (Table 1). In this context, the prevail-
ing concentrations of corticosterone and aldosterone in media
without DOC may either represent low basal endogenous pro-
duction of those compounds or residual background levels of
exogenous corticosteroids that were not completely washed-
out after change from serum containing to serum free media
(see Section 2). Incubation of cells for 24 h with the tested
concentrations of A-II and ACTH-1^24 did not a¡ect signi¢-
cantly corticosterone or aldosterone production (Table 1). This
suggests that production of corticosterone by melanoma cells is
autonomous from the exogenous supply of the normal adrenal
steroidogenic stimulants A-II and ACTH-1^24.
In summary, complementing and extending our previous
molecular studies on cutaneous expression of hypothalamic
pituitary adrenal axis components [8], we now document
that melanoma cells can metabolize rapidly and e⁄ciently
the steroid progesterone, e.g. the progesterone substrate was
consumed entirely within 24 h of incubation (Fig. 1). The
intermediates of this metabolism include DOC, corticosterone
(B) and 18OHDOC. Possible clinico-pathological and physio-
logical implications of those ¢ndings are multiple. For exam-
ple, because of the immunosuppressive properties of cortico-
sterone [12], the steroid may provide a melanoma strategy
that allows evasion from immune surveillance by the host.
At the cellular level, corticosterone could have intra- or para-
crine actions; perhaps attenuating CRH and POMC peptides
production. It is already known that these peptides are pro-
duced by melanoma cells, and that at least CRH production is
inhibited by exogenous dexamethasone [10,13^16]. Finally,
this is the ¢rst demonstration that cells of skin origin, malig-
nant melanocytes, can produce corticosteroids, providing a
strong background for further testing the hypothesis that, as
part of local defense mechanism against stress skin cells can
also produce corticosteroids [7,8]. Alternatively, these com-
pounds may be utilized as immunosuppressors by malignant
cutaneous cells.
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Table 1
Production of corticosterone and aldosterone by melanoma cells in-
cubated in serum free media for 24 h
Addition to the media Aldosterone
(pg/well)
Corticosterone
(pg/well)
No addition 8.46 þ 3.48 44.4 þ 4.92
A-II 5.16 þ 1.62 61.8 þ 11.4
ACTH-1^24 5.46 þ 2.88 49.8 þ 2.4
DOC 3.84 þ 1.2 540 þ 156
DOC plus A-II 6.48 þ 2.04 294 þ 174
DOC plus ACTH-1^24 7.49 þ 1.92 492 þ 234
The data represent mean þ S.E. (n = 4).
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